1. Home
  2. BLCO

BLCO

Bausch + Lomb Corporation

Logo Bausch + Lomb Corporation

Health Care

Ophthalmic Goods

Nasdaq

as 04-18-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Founded: 1853 Country:
Canada
Canada
Employees: N/A City: VAUGHAN
Market Cap: 5.8B IPO Year: 2022
Target Price: $19.78 AVG Volume (30 days): 463.9K
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.74 EPS Growth: N/A
52 Week Low/High: $13.62 - $21.95 Next Earning Date: 05-01-2024
Revenue: $4,146,000,000 Revenue Growth: 10.03%
Revenue Growth (this year): 14.57% Revenue Growth (next year): 5.62%

Share on Social Networks: